Fisher scientific closes Apogent merger.
Fisher estimates that 74% of its 2004 pro form revenue will be from the scientific research market, 23% from clinical labs and 3% from biopharma production. Proprietary products now account for 60% of the company products and consumables account for 80%. In its conference call, Fisher said it has finalized consolidation plans for corporate administrative functions and integration of manufacturing and distribution locations. It also said that it plans to make more acquisitions in related areas.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Executive briefing: news, trends & market intelligence for instrument executives|
|Publication:||Instrument Business Outlook|
|Article Type:||Brief Article|
|Date:||Aug 15, 2004|
|Previous Article:||The 2004 IBO design awards.|
|Next Article:||Grace acquires Alltech.|